Click a link below to view the mailing archive as if it had been sent to you.
| 2025-09-30 12:15 | | Crystalys debuts with $205M and plans for a better gout drug and more... |
| 2025-09-30 00:15 | | AZ, Daiichi's Enhertu shows early breast cancer prowess with another trial win, topping Roche's Kadcyla and more... |
| 2025-09-29 12:15 | | GSK's Emma Walmsley to step down as CEO in shock move, giving way to commercial lead Luke Miels and more... |
| 2025-09-29 00:15 | | Johnson & Johnson CEO is optimistic about pharma innovation in the U.S. despite industry challenges from the Trump administration and more... |
| 2025-09-28 00:15 | | Silicon Valley medtech giant halts H-1B hiring – Visa uncertainty puts thousands of jobs at risk |
| 2025-09-26 12:15 | | Roche, Novartis underline U.S. plans after Trump pharma tariff announcement and more... |
| 2025-09-26 00:15 | | U.S. to impose 100% tariff on branded, patented drugs unless firms build plants locally, Trump says and more... |
| 2025-09-25 12:15 | | Bristol Myers to sell psoriasis drug at over 80% discount to some US patients and more... |
| 2025-09-25 00:15 | | Biogen plots resubmission after FDA turns down high-dose Spinraza in SMA, requests more production info and more... |
| 2025-09-24 12:15 | | Generics makers to sell Gilead's Yeztugo at $40 a year under deals with Gates Foundation, others and more... |
| 2025-09-24 00:15 | | After FDA Rejection, Lexicon’s Type 1 Diabetes Drug Hit With Another Regulatory Delay and more... |
| 2025-09-23 12:15 | | Bristol Myers midtrial endpoint addition secures phase 3 win in multiple myeloma and more... |
| 2025-09-23 00:15 | | FDA turns down Lundbeck, Otsuka's Rexulti in PTSD on lack of efficacy data and more... |
| 2025-09-22 12:15 | | Pfizer inks $4.9B upfront Metsera buyout to beef up obesity pipeline following internal setbacks and more... |
| 2025-09-22 00:15 | | Merck scores FDA approval for subcutaneous Keytruda, securing potential blockbuster protection and more... |
| 2025-09-20 00:15 | | GE Healthcare exploring sale of China unit, source says and more... |
| 2025-09-19 12:15 | | Johnson & Johnson reports promising results for multiple myeloma therapy and more... |
| 2025-09-19 00:15 | | After buyout, bluebird bio hatches familiar new branding as Genetix Biotherapeutics and more... |
| 2025-09-18 12:15 | | Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug and more... |
| 2025-09-18 00:15 | | Fired CDC director says RFK Jr. aims to change childhood vaccine schedule and more... |
| 2025-09-17 12:15 | | Lilly sees obesity drug leadership beyond US as it leans on consumer-focused strategy and more... |
| 2025-09-17 00:15 | | GSK plans $30 billion US investment as pharma tariff threat looms and more... |
| 2025-09-16 12:15 | | Lilly weight-loss pill could be FDA-approved by year-end and more... |
| 2025-09-16 00:15 | | HHS taps 5 new members for CDC vaccine panel ahead of this week's meeting and more... |
| 2025-09-15 12:15 | | Novartis dives deeper into protein degraders with second Monte Rosa deal and more... |
| 2025-09-12 12:15 | | Under Trump, FDA seeks to abandon expert reviews of new drugs and more... |
| 2025-09-12 00:15 | | AbbVie settles with generic Rinvoq hopefuls, shielding the immunology med's US stronghold until 2037 and more... |
| 2025-09-11 12:15 | | Novo Nordisk tells staff to return to office full-time amid CEO's revival effort and more... |
| 2025-09-11 00:15 | | Merck executes its own Brexit, moving all R&D operations out of UK and more... |
| 2025-09-10 12:15 | | Novo Nordisk to lay off 9,000 workers in major restructuring and more... |
| 2025-09-10 00:15 | | HHS, FDA drop major DTC advertising policy changes and more... |
| 2025-09-09 12:15 | | Novartis spends $1.4B for Tourmaline and cardiovascular med that impressed in phase 2 and more... |
| 2025-09-09 00:15 | | Regeneron’s allergen-blocking antibodies score phase 3 wins against cat, pollen allergies |
| 2025-09-08 12:15 | | With 'compelling' effect size, Eli Lilly's Jaypirca advances a step closer to first-line use in CLL and more... |
| 2025-09-08 00:15 | | RFK Jr. to draw link between Tylenol and autism: Report and more... |
| 2025-09-05 12:15 | | Drug makers and payers to blame for biosimilar barriers in US market and more... |
| 2025-09-05 00:15 | | FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub and more... |
| 2025-09-04 12:15 | | Sanofi phase 3 eczema win falls short of analyst expectations and more... |
| 2025-09-04 00:15 | | Amgen-Zai stomach cancer candidate takes a turn with 'attenuated' OS benefits at final phase 3 analysis and more... |
| 2025-09-03 12:15 | | RFK Jr. critic Paul Offit iced out of key FDA vaccine panel and more... |
| 2025-09-03 00:15 | | Novo’s Wegovy cuts cardio risk by 57% versus tirzepatide and more... |
| 2025-09-02 12:15 | | Arrowhead nabs up to $2B Novartis commitment for siRNA Parkinson’s Program and more... |
| 2025-09-02 00:15 | | Eisai’s Leqembi unlocks at-home dosing with FDA autoinjector approval and more... |
